136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S115-

  Ahn, M J ^a   Yang, J ^b   Yu, H ^c   Saka, H ^d   Ramalingam, S ^e   Goto, K ^f   Kim, S W ^g   Yang, L ^h   Walding, A ^h   Oxnard, G R ⁱ  

^a Sungkyunkwan University   (South Korea)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g University of Ulsan College of Medicine   (South Korea)

^h ASTRAZENECA   (United Kingdom)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DURVALUMAB; OSIMERTINIB;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EGFR GENE; GENE MUTATION; HUMAN; MONOTHERAPY; NAUSEA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR GENE; VOMITING;

EID: 85040257501     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30246-5     Document Type: Article

References (0)